Hello to all our followers and supporters.

We were very pleased to hear that our first canine sarcoma patient Moose has been more than a year cancer free after IsoPet® Therapy. This is an excellent outcome for Moose and a strong indicator of the effectiveness of IsoPet® Therapy.

However, I am concerned, with an abundance of caution, that the news regarding a single patient does not provide a complete and balanced picture. We have worked hard to earn a reputation for complete transparency do not want to give the incorrect perception that we communicate only the most positive results. We have learned numerous things in our ongoing research and development with this revolutionary product.

Information in the medical literature indicates that soft tissue sarcomas are prone to recurrence. Moose had a successful treatment with no indication of recurrence. However, two other patients had secondary tumors that required additional therapy.

Another patient had a very large half-pound tumor. IsoPet® therapy effectively killed the tumor, but the small dog’s immune system struggled to absorb such a large mass and it became infected. The recommendation was to surgically remove it so the animal could fully heal. I just learned that she lost her fight.

In all these cases therapy effectively killed the primary tumor thereby increasing the life expectancy and quality of life of the animal. We learned that a combination of surgical removal, either before or after IsoPet® therapy, may be needed to effectively treat very large tumors. We also learned that for sarcomas, more aggressive treatment of the tumor margins may be needed to reduce the probability of recurrence.

We have been clear that the commercial treatment currently available at Vista Veterinary Hospital is considered developmental. For the first patient, a cat named Drake, the prescription dose was increased to 400 Gy and with additional emphasis placed on the margins. The tumor was close to the eye and nose so care was taken to spare those tissues. So far, we have been seeing good results for this patient.

We have compelling evidence that IsoPet® will kill the primary tumors in a single same day therapy with very high therapeutic dose and minimal collateral damage. Each tumor type has a different probability of recurrence and we will continue to gain experience as different tumor types are treated. IsoPet® is an important tool in the toolbox of veterinary medicine. It will complement other tools being used, and it definitely will improve and extend the life of many animals.

Thank you for your understanding and support of our mission. 

Dr. Michael Korenko • CEO | President, Vivos Inc.